Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Mai 2011 09:01 ET | Quelle: Tranzyme, Inc.

Tranzyme Pharma to Present Additional Phase 2 Data of Oral GI Motility Agent TZP-102 Showing Improvement of Debilitating Symptoms in Patients with Diabetic Gastroparesis

CHICAGO, May 10, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a clinical-stage biopharmaceutical company, will present Phase 2 data of TZP-102, an orally-administered ghrelin agonist in...
05. Mai 2011 05:10 ET | Quelle: Tranzyme, Inc.

Tranzyme Pharma Announces Partial Exercise of Over-Allotment Option for Initial Public Offering

RESEARCH TRIANGLE PARK, N.C., May 5, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the underwriters of its recently completed initial public offering (IPO) have...
03. Mai 2011 05:10 ET | Quelle: Tranzyme, Inc.

Tranzyme Pharma to Report First Quarter 2011 Financial Results

RESEARCH TRIANGLE PARK, N.C., May 3, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Friday, May 13, 2011 at 8:30 A.M. ET to discuss...
01. April 2011 17:18 ET | Quelle: Tranzyme, Inc.

Tranzyme Pharma Announces Pricing of Its Initial Public Offering

RESEARCH TRIANGLE PARK, N.C., April 1, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) announced today the pricing of its initial public offering of 13,500,000 shares of its common stock at...

Vorherige Seite